ALLO Stock — Allogene Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.90

Market cap

$312.0M

Cash

$388.9M

Enterprise value

-$76.9M

Balance sheet

Cash	$388.9M
Debt	$0.0M
Net cash	$388.9M
Enterprise value	-$76.9M
Basic shares	346.5M shares
Fully diluted shares	400.0M shares
Fully diluted market cap	$360.0M
Cash per share	$1.12
Quarterly burn	$32.0M
Cash runway	12.2 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

345.5M

Pre-funded warrants

0.0M

Options

37.2M

RSUs

16.2M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.2M

FDSO

400.0M

Cap table as of 2026-08-10.

Price history

Loading ALLO daily closes…

Loading price history…

Next catalyst

ALLO-329 · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	ALLO-329 RESOLUTION Phase 1, clinical and translational update	Phase 1	Not disclosed	Q4 2026
GUIDEDEst. Jul 16, 2027 in 7 mo guidance midpoint	cema-cel ALPHA3 study, interim event-free survival analysis program update · NCT06500273	Not disclosed	Not disclosed	mid-2027
Jan 12 - Feb 23 in 14 mo	cemacabtagene ansegedleucel	Phase 2	Large B-cell Lymphoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ALLO-316

Phase 1 · Active Modality: AlloCAR T cell therapy

Target CD70

Indications

advanced/metastatic renal cell carcinoma (Stage not disclosed)

Status note Phase 1b research plan completed.

cema-cel

Stage not disclosed · Active Modality: AlloCAR T cell therapy

Aliases cemacabtagene ansegedleucel, ALLO-501A

Target CD19

Indications

large B-cell lymphoma (ALPHA3) (Stage not disclosed)

Status note Filing does not state current phase in 10-Q excerpt.

ALLO-501/UCART19V1

Stage not disclosed · Terminated Modality: AlloCAR T cell therapy

Target CD19

Indications

not disclosed (Stage not disclosed)

Status note Explicitly abandoned in favor of cema-cel; license terminated.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Fludarabine
Lead indication	Large B-cell Lymphoma
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06500273	Phase 2	Recruiting	Sponsor	ALLO	—	Large B-cell Lymphoma	mid-2027 Est. Jul 16, 2027 · guidance midpoint

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Allogene Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	22,446,668	+18,650,000	1.02%	2026-08-14
RTW Investments	3,250,000	+3,250,000	0.06%	2026-08-14
DAFNA Capital	2,000,000	+629,882	0.79%	2026-08-14
Boxer Capital	1,500,000	-1,225,000	0.23%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ALLO — Allogene Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ALLO — Allogene Therapeutics Inc.